Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BMF-500

Small molecule · Inhibitor of FMS-like tyrosine kinase 3 (FLT3) · developed by Biomea Fusion

Phase 1 Most advanced trial (none active)
BMEA Developer
1 Registered trials

What is BMF-500?

BMF-500 is an orally bioavailable, covalent and selective inhibitor of FLT3, a class III receptor tyrosine kinase. It irreversibly binds a reactive cysteine in the FLT3 active site, blocking FLT3-mediated downstream signaling and proliferation of FLT3-expressing cancer cells. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
FMS-like tyrosine kinase 3 (FLT3)
Mechanism
Inhibitor of FMS-like tyrosine kinase 3 (FLT3)
Pathways
FLT3-mediated downstream signaling, cancer cell proliferation
Therapy area
Oncology
Developer
Biomea Fusion Inc. (BMEA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05918692 Phase 1 Acute Myeloid Leukemia Completed BMEA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia

Other drugs acting on FLT3

Gilteritinib FDA approved Midostaurin FDA approved Pexidartinib FDA approved CDX-301 Phase 2 CLN-049 Phase 1 Dapolsertib Phase 1/2 Lomonitinib Phase 2/3

More from Biomea Fusion

BMF-650 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BMEA page.

Follow BMEA, the company behind BMF-500

See BMEA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMEA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.